Skip to main content

BRIEF-IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm

* INTELGENX RECEIVES HEALTH CANADA CLEARANCE TO BEGIN PHASE 2A STUDY WITH MONTELUKAST VERSAFILM(TM) IN MILD TO MODERATE ALZHEIMER'S DISEASE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.